153 related articles for article (PubMed ID: 20425807)
1. Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance.
Ojeda-Uribe M; Caron C; Itzhar-Baikian N; Debliquis A
Am J Hematol; 2010 May; 85(5):396. PubMed ID: 20425807
[No Abstract] [Full Text] [Related]
2. Acquired von Willebrand syndrome in a patient with monoclonal gammopathy of undetermined significance.
Puronen CE; Josephson NC; Broudy VC
Blood Coagul Fibrinolysis; 2013 Jun; 24(4):430-2. PubMed ID: 23249617
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant).
Sobas MA; Alonso Vence N; Diaz Arias J; Bendaña Lopez A; Fraga Rodriguez M; Bello Lopez JL
Ann Hematol; 2010 Feb; 89(2):217-9. PubMed ID: 19636554
[No Abstract] [Full Text] [Related]
4. Successful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy.
Green A; Shen YP; Nelson AT; Sarode R; Ibrahim IF; Cao J; Afraz S; Yates SG
Ann Hematol; 2022 Dec; 101(12):2627-2631. PubMed ID: 36194257
[TBL] [Abstract][Full Text] [Related]
5. Response to bortezomib in refractory type I cryoglobulinemia.
Talamo G; Claxton D; Tricot G; Fink L; Zangari M
Am J Hematol; 2008 Nov; 83(11):883-4. PubMed ID: 18756542
[No Abstract] [Full Text] [Related]
6. Bortezomib in lung transplantation: a promising start.
Neumann J; Schio S; Tarrasconi H; Bortolotto A; Costa C; Machuca T; Camargo S; Sanchez L; Michelon T; Canabarro R; Sporleder H; Fernandes S; Camargo J; Perin F; Felicetti J
Clin Transpl; 2009; ():421-4. PubMed ID: 20524308
[No Abstract] [Full Text] [Related]
7. Renal Fanconi syndrome as a cause of chronic kidney disease in patients with monoclonal gammopathy of undetermined significance: partially reversed renal function by high-dose dexamethasone with bortezomib.
Nishida Y; Iwama K; Yamakura M; Takeuchi M; Matsue K
Leuk Lymphoma; 2012 Sep; 53(9):1804-6. PubMed ID: 22385229
[No Abstract] [Full Text] [Related]
8. Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome.
Luboshitz J; Lubetsky A; Schliamser L; Kotler A; Tamarin I; Inbal A
Thromb Haemost; 2001 May; 85(5):806-9. PubMed ID: 11372672
[TBL] [Abstract][Full Text] [Related]
9. Acquired von willebrand syndrome secondary to monoclonal gammopathy of undetermined significance: long-term remission after treatment with bortezomib.
Saldanha A; Veiga ME; Okazaki E; Rothschild C; Martinez G; Rocha V; Orsi FA; Villaca P
J Thromb Thrombolysis; 2023 May; 55(4):770-774. PubMed ID: 37000318
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib for the treatment of refractory Type-1 cryoglobulinaemia.
Spizzo G; Mitterer M; Gunsilius E
Br J Haematol; 2010 Jul; 150(2):235-7. PubMed ID: 20346005
[No Abstract] [Full Text] [Related]
11. Acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance.
Yujiri T; Nakamura Y; Oota I; Nakano K; Tanizawa Y
Ann Hematol; 2014 Aug; 93(8):1427-8. PubMed ID: 24337448
[No Abstract] [Full Text] [Related]
12. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease.
Hess G; Wagner V; Kreft A; Heussel CP; Huber C
Br J Haematol; 2006 Sep; 134(5):544-5. PubMed ID: 16856889
[No Abstract] [Full Text] [Related]
13. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.
Mai HL; Cesbron A; Brouard S; Blanchol G; Cantarovich D; Dantal J; Hourmant M; Lino M; Meurette A; Gosselin M; Abbadie O; Soulillou JP; Giral M
Clin Transpl; 2009; ():361-8. PubMed ID: 20524299
[No Abstract] [Full Text] [Related]
14. Bortezomib in multiple myeloma.
Meisler AI
N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
[No Abstract] [Full Text] [Related]
15. Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case report.
Patel JK; Everly MJ; Kittleson M; Kobashigawa JA
Clin Transpl; 2009; ():347-9. PubMed ID: 20524297
[No Abstract] [Full Text] [Related]
16. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients.
Trivedi HL; Terasaki PI; Feroz A; Vanikar AV; Trivedi VB; Khemchandani SI; Dave SD; Shankar V; Modi PR; Kaneku H; Idica A; Everly MJ
Transplantation; 2010 Jul; 90(2):221-2. PubMed ID: 20644455
[No Abstract] [Full Text] [Related]
17. Low-dosage intravenous immunoglobulin in the management of a patient with acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance.
Hayashi T; Yagi H; Suzuki H; Nonaka Y; Nomura T; Sakurai Y; Shibata M; Matsumoto M; Yamamoto Y; Fujimura Y
Pathophysiol Haemost Thromb; 2002; 32(1):33-9. PubMed ID: 12214161
[TBL] [Abstract][Full Text] [Related]
18. Acute humoral rejection in a lung recipient: reversion with bortezomib.
Neumann J; Tarrasconi H; Bortolotto A; Machuca T; Canabarro R; Sporleder H; Fernandes S; Schio S; Costa C; Camargo S; Sanchez L; Camargo J; Perin F; Felicetti J; Michelon T
Transplantation; 2010 Jan; 89(1):125-6. PubMed ID: 20061929
[No Abstract] [Full Text] [Related]
19. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):577-88. PubMed ID: 16977568
[TBL] [Abstract][Full Text] [Related]
20. Perspective on the current use of bortezomib in multiple myeloma.
San-Miguel J; Bladé J
Haematologica; 2006 Jul; 91(7):871-2. PubMed ID: 16818272
[No Abstract] [Full Text] [Related]
[Next] [New Search]
